Abeona Therapeutics (ABEO) vs Benitec Biopharma (BNTC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Abeona Therapeutics (ABEO) has outperformed Benitec Biopharma (BNTC) over the past year, losing 3.2% versus a loss of 34.8%. Over five years, ABEO leads with a -77.7% price change compared with -85.3% for BNTC. Benitec Biopharma is the larger company by market cap ($313.6 million vs $290.5 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ABEO | BNTC |
|---|---|---|
| Share price | $5.08 | $8.99 |
| Market cap | $290.49M | $313.60M |
| 1-day change | +1.40% | -0.11% |
| YTD return | -3.61% | -33.26% |
| 1-year return | -3.24% | -34.76% |
| 5-year return | -77.67% | -85.27% |
| EPS (TTM) | $-1.20 | $-0.98 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $7.65 | $16.76 |
| 52-week low | $4.00 | $8.52 |
| Distance from 52-week high | -33.59% | -46.36% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +271.65% | +170.63% |
| Average volume | 1.42M | 150.34K |
| Shares outstanding | 57.18M | 34.88M |
| Employees | 226 | 24 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ABEO has outperformed BNTC by 31.5 percentage points over the past year.
About Abeona Therapeutics
ABEO stock →Abeona Therapeutics Inc., a commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States. It develops ZEVASKYN, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa.
Healthcare · Biotechnology · 226 employees
About Benitec Biopharma
BNTC stock →Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines in the United States. Its Silence and Replace, a DNA-directedRNA interference platform, that combines RNA interference with gene therapy to create medicines which simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct.
Healthcare · Biotechnology · 24 employees
ABEO vs BNTC FAQ
Which is bigger, Abeona Therapeutics or Benitec Biopharma?
Benitec Biopharma (BNTC) is larger, with a market capitalization of $313.60M compared with $290.49M for Abeona Therapeutics (ABEO).
Which stock has performed better over the past year, ABEO or BNTC?
ABEO returned -3.24% over the past 12 months, compared with -34.76% for BNTC (price return, excluding dividends). Past performance does not predict future results.
Are Abeona Therapeutics and Benitec Biopharma in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.